Armata Pharmaceuticals Inc
AMEX:ARMP
Armata Pharmaceuticals Inc
Net Change in Cash
Armata Pharmaceuticals Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Armata Pharmaceuticals Inc
AMEX:ARMP
|
Net Change in Cash
-$26.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$12.9B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-49%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
$3.2B
|
CAGR 3-Years
140%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$898m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
-$4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
$483.2m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
27%
|
|
Armata Pharmaceuticals Inc
Glance View
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
See Also
What is Armata Pharmaceuticals Inc's Net Change in Cash?
Net Change in Cash
-26.3m
USD
Based on the financial report for Mar 31, 2025, Armata Pharmaceuticals Inc's Net Change in Cash amounts to -26.3m USD.
You don't have any saved screeners yet